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Abstract
Introduction: Osteopoenia and osteoporosis because of hyperprolactinaemia caused by prolactinoma may be followed by
an increased risk of fracture. There are no data on the bone effects of functional hyperprolactinaemia. The aim was to assess
the influence of hyperprolactinaemia of various origins on bone turnover and density in different skeletal sites.
Material and methods: The study was carried out in 75 women (aged 30.53 – 7.8): Group I  32 women with prolactino-
ma and Group II  43 women with functional hyperprolactinaemia. Both groups of patients were subdivided into those
with hypogonadism and those with normal gonadal function. The control group consisted of 29 healthy women aged
(33.59 – 4.7). In all subjects PRL and bone turnover markers (BAP, OC, ICTP) were studied. BMD measurements (lumbar
spine, forearm, proximal femur and total body) were carried out using DXA.
Results: Higher PRL concentrations were observed in patients than in controls. The values of bone turnover markers (BAP,
ICTP) were shown to be higher in patient groups and subgroups than in controls. In patients with prolactinoma lumbar
spine BMD was lower than in patients with functional hyperprolactinaemia and controls. Total body BMD was also lower,
albeit to a lesser extent.
Conclusions: Hyperprolactinaemia caused by prolactinoma in women influences bone metabolism unfavourably, more
by the impact on the activity of bone turnover markers than on BMD. This provides an opportunity for earlier assessment
of bone metabolism disturbances before the BMD changes can be observed. Functional hyperprolactinaemia does not
determine such a harmful effect on bone metabolism as hyperprolactinemia due to prolactinoma.
(Pol J Endocrinol 2007; 58 (2): 116122)
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Streszczenie
WstŒp: Osteopenia i osteoporoza w wyniku hiperprolaktynemii spowodowanej przez prolaktynoma mog„ zwiŒkszaæ
ryzyko z‡amaæ. Obecnie brakuje danych w odniesieniu do czynnociowej hiperprolaktynemii. Celem pracy by‡a ocena
wp‡ywu hiperprolaktynemii ró¿nego pochodzenia na przebudowŒ i gŒstoæ koci w ró¿nych miejscach szkieletu.
Materia‡ i metody: W badaniu uczestniczy‡o 75 kobiet (wiek 30,53 – 7,8). Do grupy I nale¿a‡y 32 kobiety z prolaktynoma,
natomiast do grupy II  43 kobiety z czynnociow„ hiperprolaktynemi„. Obie grupy podzielono na pacjentki z hipogona-
dyzmem i prawid‡ow„ czynnoci„ gonad. W sk‡ad grupy kontrolnej wesz‡o 29 zdrowych kobiet (wiek 33,59 – 4,7).
U wszystkich badanych oznaczano stŒ¿enie PRL i markerów przebudowy koci (BAP, OC, ICTP). GŒstoæ mineralna koci
(BMD, bone mineral density) (krŒgos‡upa lŒdwiowego, przedramienia, bli¿szej nasady uda i ca‡ego cia‡a) zbadano metod„ DXA.
Wyniki: WiŒksze stŒ¿enia PRL stwierdzono u pacjentek ni¿ w grupie kontrolnej. WiŒksze wartoci markerów przebudo-
wy koci wykazano w grupach i podgrupach pacjentek ni¿ w grupie kontrolnej. U pacjentek z prolaktynoma wartoci
BMD krŒgos‡upa lŒdwiowego by‡y mniejsze ni¿ u pacjentek z czynnociow„ hiperprolaktynemi„ i w grupie kontrolnej.
GŒstoæ mineralna koci ca‡ego cia‡a by‡a równie¿ obni¿ona, ale w mniejszym stopniu.
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Wnioski: Hiperprolaktynemia, spowodowana przez prolaktynoma u kobiet, wp‡ywa niekorzystnie na metabolizm kost-
ny, bardziej przez dzia‡anie na aktywnoæ markerów przebudowy koci ni¿ na BMD, co umo¿liwia wczesn„ ocenŒ zabu-
rzeæ metabolizmu koci, zanim wyst„pi„ zmiany w BMD. Warto wspomnieæ, ¿e czynnociowa hiperprolaktynemia nie
wywiera tak niekorzystnego wp‡ywu na koci jak prolaktynoma.
(Endokrynol Pol 2007; 58 (2): 116122)
S‡owa kluczowe: prolaktynoma, czynnociowa hiperprolaktynemia, gŒstoæ koci, przebudowa koci
Introduction
Hyperprolactinaemia is the most common disorder of
the hypothalamic-hypophyseal system. It may be cau-
sed by prolactin-secreting adenoma (prolactinoma),
another pituitary tumour, primary hypothyroidism,
renal failure or particular medication. Physiologically,
hyperprolactinaemia occurs in pregnancy, during lac-
tation, sexual intercourse, breast nipple irritation, phy-
sical exercise, stress or sleep. Spontaneous serum pro-
lactin (PRL) concentration elevations in subjects without
pituitary tumour and with no clinical signs of hypotha-
lamic or pituitary stalk disturbances are regarded as
functional hyperprolactinaemia [13].
Clinical symptoms of hyperprolactinaemia, regardless
of its origin, are sterility, menstrual disturbances and ga-
lactorrhoea in women and impotence and libido loss in
men. Other important metabolic sequelae of persistent
hyperprolactinaemia are decreased bone mineral density
(BMD) and increased activity of bone turnover markers
in both sexes. Data on these harmful bone effects regard
patients with prolactin-secreting pituitary tumours, owing
to hypogonadism and a decrease in oestrogen secretion
[46]. Successful treatment of hyperprolactinaemia re-
stores normal bone turnover and bone mass, but these
changes occur after some time [7, 8]. There is a signifi-
cant relative risk of osteoporosis in women harbouring
prolactinoma, estimated as factor 4.5. Moreover, untre-
ated hyperprolactinaemia is associated with an incre-
ased fracture risk even before the menopause [9, 10].
There is no data in the literature on the influence of
functional hyperprolactinaemia on bone metabolism.
Moreover, previous studies on bones in hyperprolacti-
naemia utilised older methods such as computed to-
mography or photon absorptiometry and the studies
were carried out in limited skeletal localisations [1113].
Dual X-ray absorptiometry (DXA) is a modern densito-
metric technique and is accepted world-wide as the
gold standard for BMD studies [14].
The aim of this study was to assess the influence of
hyperprolactinaemia of different origins on bone tur-
nover activity and bone mineral density as measured
by DXA in various skeletal sites.
Material and methods
Subjects
Seventy five women aged 1949 years (mean age 30.53 –
– 7.8) were recruited for the study from the patients of
the Department of Endocrinology, Diabetology and Iso-
tope Therapy, Wroc‡aw Medical University. The sub-
jects were divided into the following three groups: Gro-
up I  32 women with prolactinoma, Group II  43
women with functional hyperprolactinaemia and Gro-
up III  29 healthy women (control group). Pituitary
MRI scans and a PRL stimulation test (0, 60) before
and following 10 mg of metoclopramide given orally
(the metoclopramide test) were performed, and patients
were assigned to the hyperprolactinaemia group on the
basis of the results of the scan and the test (Group I
 adenoma on MRI and normal PRL response; Group II
 no adenoma on MRI and exaggerated PRL respon-
se). The exclusion criteria were other diseases or medi-
cation known to promote bone loss, treated osteoporo-
sis, chronic liver and renal diseases and neoplasms.
Groups I and II were subdivided according to the pre-
sence of hypogonadism assessed on the basis of the pre-
sence of oligo- or amenorrhoea. The controls had regu-
lar menses, PRL concentration in the normal range, nor-
mal gonadal function and no galactorrhoea. The subjects
did not differ regarding body weight, height and BMI.
Patients with prolactinoma and concomitant hypogona-
dism, with functional hyperprolactinaemia and with
functional hyperprolactinaemia with hypogonadism
were younger than the controls (p = 0.008; 0.007; 0.0002,
respectively). Among the patients with functional hyper-
prolactinaemia, those with hypogonadism were youn-
ger than those with normal gonadal function (p = 0.02).
The characteristics of the subjects are shown in Table I.
Of 32 patients harbouring prolactinoma, macroade-
noma was present in 7 cases (21%) and the remaining
25 had microadenoma. The patients did not differ from
the controls regarding diet, smoking habits, caffeine or
alcohol ingestion and physical activity. All subjects had
normal thyroid, renal and liver function and had rece-
ived no medication three months prior to or during the
study. Analysis of the anamnestic data of the patients
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showed that there were no differences in mean dura-
tion of symptoms or mean period of previous therapy
between the groups and subgroups of the patients with
hyperprolactinaemia. The protocol of the study was
accepted by the local Bioethics Committee, and all the
subjects gave their informed consent.
Methods
PRL serum concentrations were studied by the chemi-
luminescent method using the Immulite 2000-PRL kit
(DPC, USA), the normal range for women 1.925 ng/ml.
The bone turnover markers studied were bone fraction
of alkaline phosphatase (BAP) by the thermic method
using Enzyline PAL optimise (bioMerieux, France), nor-
mal range 100290 U/l, osteocalcin (OC) by the immu-
noradiometric method using OSTEO-RIACT (CIS
Bio International, France), normal range 7.739.4 ng/ml,
and C-terminal telopeptide of type I collagen (ICTP) by
radioimmunoassay using UNIQ ICTP RIA (Orion Dia-
gnostica, Finland), normal range 2.15.6 µg/l.
Bone mineral density (BMD) was studied by DXA
using Lunar DPX-plus (Lunar Corp., USA). The follo-
wing were analysed: the lumbar spine (L2L4) in the
anteroposterior projection, the proximal femur (femo-
ral neck, trochanter major, Wards triangle), the fore-
arm (ultradistal radius, distal 1/3 radius) and the total
body. The densitometric results were expressed in me-
asured units (g/cm2) and in standard deviations (SD)
with respect to age-matched (Z-score) BMD.
Statistical analysis
Statistical analysis was performed using the STATISTI-
CA software for Windows, version 6.0. Means – SD
were analysed among groups by means of Students
t-test when normally distributed, or by means of
Mann-Whitneys ranking sums test when not. As
a level of statistical significance a p value of < 0.05
was used.
Results
The highest PRL level was revealed in Group I (prolacti-
noma), followed by Group II (functional hyperprolactina-
emia), both of which had significantly higher levels in sta-
tistical terms than the control group (p = 0.000000 for both).
Furthermore, the PRL level in Group I was higher than in
Group II (p = 0.00002). The PRL levels of the patients with
prolactinoma were higher than in the controls and this
was true both in the subgroup with hypogonadism (p =
= 0.000001) and in the subgroup without hypogonadism
(normal menses) (p = 0.000000). Similarly, patients with
functional hyperprolactinaemia had higher PRL than the
controls, both the subgroup with hypogonadism (p =
= 0.000000) and that without (p = 0.000002) (Table 1, Fig. 1).
Table I
General characteristics of the group studied (anthropometric parameters and serum PRL concentration)
Tabela I
Ogólna charakterystyka badanych grup (parametry antropometryczne i stŒ¿enie prolaktyny [PRL] w surowicy)
Group Number Age (years) Body mass (kg) Height (cm) PRL [ng/ml]
I  prolactinoma 32 30.96–8.18 62.53–9.31 165.84–5.39 90.71–81.65*#
Hypogonadism present 14 28.14–7.88* 59.85–7.76 166.07–6.06 119.42–113.85*
Hypogonadism absent 18 33.16–7.93 64.61–10.08 165.66–4.98 69.56–40.68*
II  functional hyperprolactinemia 43 30.20–7.59* 61.25–10.71 164.83–5.33 35.98–27.26*#
Hypogonadism present 27 28.22–6.41*$ 60.74–11.76 163.74–4.70 37.23–28.85*
Hypogonadism absent 16 33.56–8.42$ 62.12–8.97 166.68–5.95 33.74–24.95*
III  control group 29 33.59–4.70 61.70–10.58 163.85–5.37 8.57–4.81
*p < 0.05 in comparison with control group; #p < 0.05 in comparison between groups; $p < 0.05 in comparison between subgroups
Figure 1. Serum prolactin (PRL) concentration in groups
of patients with hyperprolactinaemia and in the control group;
*p < 0.05 in comparison with control group; #p < 0.05 in
comparison between groups
Rycina 1. StŒ¿enie prolaktyny (PRL) w surowicy w grupach
pacjentek z hiperprolaktynemi„ i w grupie kontrolnej; *p < 0,05
w porównaniu z grup„ kontroln„; #p < 0,05 miŒdzy grupami
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Mean BAP activity was higher in Group I and Gro-
up II than in controls (p = 0.015; 0.04, respectively).
Among Group I patients, BAP activity was higher than
in controls, both in the subgroup with hypogonadism
(p = 0.02) and in that with normal gonadal function
(p = 0.03). It was also higher than in controls in hypo-
gonadal patients from Group II (p = 0.007). Mean ICTP
levels were higher in Groups I and II than in the con-
trol group (p = 0.0005; 0.0009 respectively). In addition,
ICTP levels were higher in all subgroups of patients than
in controls (p = 0.00003; 0.02; 0.0008; 0.01 respectively).
There were no differences in OC levels between the
groups studied and controls (Table II).
Mean lumbar spine BMD values expressed in units
and Z-score were lower in Group I than in controls
(p = 0.001; 0.0008 respectively). Lumbar spine BMD va-
lues expressed by Z-score were lower in Group I than
in Group II (p = 0.04) (Fig. 2). Hypogonadal patients
from Group I had a lower lumbar spine BMD assessed
by units and Z-score than controls (p = 0.0002; 0.0005
respectively). Patients from Group I with normal gona-
dal function also had lower BMD assessed by units and
Z-score than controls (p = 0.04; 0.02, respectively (Table III).
Mean total body BMD in units and Z-score was lo-
wer in Group I than in controls (p = 0.01; 0.02 respecti-
vely) (Fig. 3). Hypogonadal patients from Group I
had lower total body BMD in units and Z-score than
controls (p = 0.01; 0.04, respectively). Patients from Gro-
up I with normal gonadal function had a lower total body
BMD Z-score (p = 0.04) than controls (Table III).
Discussion
Persistent hyperprolactinaemia is usually followed by
bone metabolism deterioration, causing increased
bone resorption, bone loss and an increased risk of
fractures. These are thought to be consequences of
hypogonadotropic hypogonadism caused by hy-
perprolactinaemia and the direct effect of PRL on the
bones [5, 9, 10]. From this point of view, early detec-
tion of these hormonal disturbances as the cause of
secondary osteoporosis is of great importance for the
possible prevention of fractures [1, 15]. To our know-
ledge, the present study is the first to focus on bone
metabolism changes in patients with functional hy-
perprolactinaemia.
Table II
Bone turnover markers: bone fraction of alkaline phosphatase (BAP), osteocalcin (OC) and C-terminal telopeptide of type I
collagen (ICTP) in groups and subgroups studied and in the control group
Tabela II
Markery przebudowy koci: frakcja kostna fosfatazy alkalicznej (BAP), osteokalcyna (OC) i C-koæcowy telopeptyd kolagenu
typu 1 (ICTP) w badanych grupach i podgrupach pacjentek i w grupie kontrolnej
Group BAP OC ICTP
(U/L) [ng/ml] [µg/l]
I  prolactinoma 40.89–22.31* 29.68–5.58 3.02–0.86*
Hypogonadism present 42.21–24.18* 29.64–5.83 3.22–0.74*
Hypogonadism absent 39.96–21.60* 29.72–5.55 2.84–0.95*
II  functional hyperprolactinemia 36.63–16.71* 29.57–10.0 2.96–0.91*
Hypogonadism present 39.12–17.61* 31.10–10.46 3.12–1.06*
Hypogonadism absent 31.45–13.90 26.95–8.9 2.69–0.52*
III  control group 28.50–14.25 27.79–5.29 2.25–0.45
*p < 0.05 in comparison with control group
Figure 2. Lumbar spine BMD (Z-score) in groups of patients with
hyperprolactinaemia and in the control group; *p < 0.05 in comparison
with control group; #p < 0.05 in comparison between groups
Rycina 2. GŒstoæ mineralna koci (BMD) krŒgos‡upa
lŒdwiowego (Z-score) w grupach pacjentek z hiperprolaktynemi„
i w grupie kontrolnej; *p < 0,05 w porównaniu z grup„ kontroln„;
#p < 0,05 miŒdzy grupami
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We observed higher PRL levels in our patients with
prolactinoma than in patients with functional hyper-
prolactinaemia and the control group. PRL levels in
functional hyperprolactinaemia were also higher than
in controls. These differences from the controls were
significant regardless of gonadal dysfunction in hyper-
prolactinaemic patients, but the higher PRL concentra-
tions were in hypogonadal patients. These observations
confirm the association of the level of hyperprolactina-
emia with the presence of prolactinoma and disturban-
ces of gonadal function [1, 5].
In the current study two bone formation markers
(BAP and OC) and one resorption marker (ICTP) were
studied. The levels of BAP and ICTP were observed to
be higher in the patients with prolactinoma and func-
tional hyperprolactinaemia than in the control group.
It is difficult to explain the absence of changes in OC
levels in our groups, current data being supported by
other observations of higher bone turnover in hyper-
prolactinaemia followed by increased bone loss later on
[7, 8]. The bone turnover processes are coupled to each
other, so that the initial increase in the resorption is as-
sociated with an increase in bone formation some time
later. The consequences of the increased bone turnover
because of untreated hyperprolactinaemia are a decre-
ase in BMD and an increase in fracture risk [10, 16]. In
some studies an increase in bone resorption and for-
mation activity has been observed in hyperprolactina-
emia, while there has been no change in OC levels, as
in our results. Others point to decreased formation to-
gether with increased bone resorption, both of which
normalised during therapy [7, 1719]. In another work
the therapy normalised decreased bone formation but
bone resorption remained at the higher level [8]. In the
present study the acute effect of current therapy was
not analysed. This will be possible in the future, follo-
wing repeated measurements after successful PRL-nor-
malising therapy. Some studies show higher values for
bone turnover markers in hyperprolactinaemic patients
with hypogonadism [18]. No differences were shown
between subgroups in terms of the gonadal status of
our patients. This observation may suggest the utility
of bone turnover markers in the early diagnostics of
bone metabolism deterioration because of hyperprolac-
tinaemia before the BMD changes occur [8].
Table III
Lumbar spine (L2L4) and total body BMD expressed in measured units (g/cm
2) and Z-score values in groups and subgroups
studied and in the control group
Tabela III
GŒstoæ mineralna koci (BMD) krŒgos‡upa lŒdwiowego (L2L4) i ca‡ego cia‡a wyra¿one w jednostkach pomiaru (g/cm
2)
i wartociach Z-score w grupach i podgrupach pacjentek i w grupie kontrolnej
Group L2L4 L2L4 Total body Total body
BMD Z-score BMD Z-score
[g/cm2] (SD) [g/cm2] (SD)
I  prolactinoma 1.190–0.10* 0.056–1.06*# 1.107–0.07* 0.096–0.81*
Hypogonadism present 1.148–0.16* 0.235–1.04* 1.098–0.07* 0.095–0.79*
Hypogonadism absent 1.232–0.15* 0.295–1.04* 1.115–0.07 0.098–0.85*
II  functional hyperprolactinaemia 1.263–0.19 0.662–1.36# 1.127–0.08 0.221–0.80
Hypogonadism present 1.246–0.17 0.531–1.38 1.128–0.08 0.230–0.78
Hypogonadism absent 1.291–0.17 0.883–1.35 1.125–0.08 0.204–0.88
III  control group 1.320–0.16 1.073–0.93 1.153–0.05 0.421–0.59
*p < 0.05 in comparison with control group; #p < 0.05 in comparison between groups
Figure 3. Total body BMD (Z-score) in groups of patients with
hyperprolactinaemia and in the control group; *p < 0.05 in
comparison with control group
Rycina 3. GŒstoæ mineralna koci (BMD) ca‡ego cia‡a (Z-score)
w grupach pacjentek z hiperprolaktynemi„ i w grupie kontrolnej;
*p < 0,05 w porównaniu z grup„ kontroln„; #p < 0,05 miŒdzy grupami
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We have shown lumbar spine BMD to be lower in
female patients harbouring prolactinoma than in con-
trols. BMD values were also lower in patients with pro-
lactinoma than in those with functional hyperprolacti-
naemia. Both hypogonadal patients with prolactinoma
and those with normal gonadal function had lower lum-
bar spine BMD than the controls. The lumbar spine con-
tains mainly trabecular bone, and this bone is very sen-
sitive to metabolic influences such as sex hormone de-
ficiency. Our patients were at reproductive age, and
the decrease in Z-score is the most reliable marker of
bone loss in premenopausal subjects [14]. This indica-
tes greater bone deterioration in prolactinoma than in
functional hyperprolactinaemia. Differences in age be-
tween the groups studied had no significant influence
on the BMD results since they were present when expres-
sed in the Z-scores, which were also age-dependent.
No significant differences in BMD were observed
between the hyperprolactinaemic patients and controls
in the proximal femur and forearm. Total body densi-
tometry revealed lower BMD values in patients with
prolactinoma than in controls. The lowest values were
shown in the subgroup with hypogonadism. Total body
densitometry reflects the cortical bone and this measu-
rement has great value in children and adolescents [14],
while being of less value in adults of reproductive age,
as our subjects were.
We observed a loss of BMD of about 11% within the
lumbar spine in patients with prolactinoma, and bone
loss of about 4% in the total body scans. The difference
in bone loss between prolactinoma and functional hy-
perprolactinaemia was about 7%. The deterioration in
trabecular bone, although not great, may lead to frac-
tures in the future. Other studies showed similar, or
even greater, bone loss in hyperprolactinaemic patients,
mainly regarding trabecular bone [13, 20, 21]. Schlech-
te et al. showed a decrease in vertebral BMD in hyper-
prolactinaemia as compared to controls but not in the
forearm (cortical bone) [13]. These data support our ob-
servation that hyperprolactinaemia has a greater influ-
ence on the trabecular bone. In another study amenor-
rhoeic patients with hyperprolactinaemia showed BMD
17% lower in the cortical bone but 1535% lower in the
trabecular bone [22]. Some studies have indicated that
regularly menstruating women have higher lumbar
spine BMD than those with menstrual disturbances [23
25]. Kayath et al. revealed a positive correlation be-
tween years of hypogonadism and the extent of bone
loss within the spine and femoral neck [12].
The current study is one of the first to utilise the
DXA method to assess BMD in all possible measure-
ment sites, previous studies having been limited to the
spine and forearm [13, 25], spine and femoral neck [7, 10]
or spine only [20, 26]. Apart from DXA, other techniqu-
es such as quantitative computed tomography [13, 15,
25], single-photon absorptiometry [17, 25] and quanti-
tative ultrasound [9] have been used.
We did not identify any differences in BMD and
bone turnover between patients who had been treated
in the past and those who had not. The data from the
literature show that medical therapy of hyperprolacti-
naemia does not completely normalise bone metabo-
lism. The therapy increases BMD but does not restore
normal BMD, even several years following normalisa-
tion of gonadal function [20, 27, 28]. The greatest BMD
loss in untreated hyperprolactinaemia occurs within the
initial two years of menstrual disturbance [17, 25]. Pa-
tients with gonadal function restored by therapy had
slightly higher BMD values than those untreated yet
significantly lower than controls [28]. The greatest in-
crease in BMD was recorded following 612 months of
therapy [7, 20, 27], but even 18 months of therapy did
not restore normal BMD and bone turnover, regardless
of gonadal function normalisation [8].
Conclusions
1. Hyperprolactinaemia caused by prolactinoma in
women unfavourably influences bone metabolism
more by the impact on the activity of bone turnover
markers than on BMD. It gives an opportunity for
earlier assessment of bone deterioration before BMD
changes occur.
2. Functional hyperprolactinaemia does not determi-
ne such a harmful effect on bone metabolism as hy-
perprolactinaemia due to prolactinoma.
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